듀오블레이드

Existing electrosurgical units (electric scalpels) used in operating rooms dissect and cauterize tissue using high heat of over 400℃, which meansSurgical Smokeis generated in large quantities. This smoke contains harmful substances, posing a risk to the health of medical personnel and obstructing the view, thereby reducing surgical accuracy.

Additionally, burning tissue with high heat can cause damage and charring of surrounding tissue, leading to slower recovery and increased risk of complications. Previously, separate smoke evacuation devices were needed to remove the smoke, and there were no suitable alternatives to reduce thermal damage.

DuoBlade simultaneously performs tissue dissection and hemostasis at a low temperature of approximately 100℃ or less. The dielectric heating (DUO) technology, which heats only the moisture inside cells, prevents tissue carbonization, immediately stops bleeding, and significantly reduces the generation of surgical smoke as a result.

Thanks to this, the surgical view is clear, the working environment for OR staff is improved, and patient recovery is faster with a lower risk of complications due to reduced thermal damage. It has been approved by the FDA, proving its safety and effectiveness, and is an immediately field-applicable solution that complies with surgical smoke regulations introduced in 17 states. A major advantage is that it maintains clinical performance equivalent to premium energy equipment compared to existing similar products, while lowering the price to increase accessibility.

Hospitals and surgical centers (B2B)are the main customers. Surgeons and medical institutions purchase and use it, and hospitals in areas where smoke mandatory regulations have been introduced are expected to have priority demand.

In addition, supply through surgical device distributors or medical device rental companies is also expected. Ultimately, it targets the global medical market, and FDA approval in the United States has made it possible for US hospitals to adopt it. It is not a product that general patients or consumers purchase directly, but is introduced in the form of business-to-business transactions.

As a medical device, regulatory approvals (such as CE certification) must be obtained sequentially in each country, but the concept itself is universal and can be used in any operating room worldwide. It has already been approved in the United States, and global expansion is expected in Europe, Asia, etc.

Specific applications are in general surgery, so it is not limited to a specific country or environment. Furthermore, this low-temperature resection technology can be applied to robotic surgery platforms or endoscopic surgical instruments in the future, so it has the potential to expand into other fields within the medical industry. On the other hand, due to the nature of the medical field, sequentially overcoming entry barriers such as licensing and insurance coverage requires time and expense.

It is well-received for its high level of technical completeness and the fact that real-world use verification has been conducted. At the CES Innovation Awards, it was recognized as a practical innovation that simultaneously improves the safety of medical personnel and patient recovery.

Industry experts are reacting with comments such as "a game-changer that fundamentally solves the problem of surgical smoke," and it is evaluated as a timely product, especially in line with the trend of mandatory smoke removal in some US states. Market expectations have also increased further due to the FDA approval, but there are also realistic concerns that securing a sales network will be key in competition with large medical device companies.

Overall, it is a somewhat undervalued hidden champion rather than an overvalued one, and its reputation is likely to rise rapidly after commercialization.